News 22.06.2021 Schlieren (Zurich), Switzerland, 22, 2021 – Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on preclinical re-search in the musculoskeletal field, on the mechanism of action of its MagnetOs bone graft. The paper describes how immunomodulation by bone grafts with submicron...
News 16.06.2021 Zurich-Schlieren, Switzerland, June 16, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") at a public offering price...
News 14.06.2021 Zurich-Schlieren, Switzerland, June 13, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of...
News 09.06.2021 Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") pursuant to a registration...
News 02.06.2021 Schlieren (Zurich), Switzerland, June 2, 2021 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor networks both exceeding management expectations. Direct sales of MagnetOs in the U.S. accelerated in...